Industry
Biotechnology
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Loading...
Open
1.45
Mkt cap
1.6M
Volume
836K
High
1.88
P/E Ratio
N/A
52-wk high
42.35
Low
1.45
Div yield
N/A
52-wk low
1.34
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 11:52 am
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 11:56 am
Portfolio Pulse from Avi Kapoor
September 17, 2024 | 9:48 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:40 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 11:47 am
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 12:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.